Comparing two antibiotics for liver failure patients with hospital-acquired infections
Treatments studied
Part of Digestive system clinical trials.
This study compares two strong antibiotics to see which one works better for people with liver failure who get a hospital-acquired infection caused by resistant bacteria. The two drugs are ceftazidime-avibactam and a higher dose of meropenem given as an extended infusion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with acute-on-chronic liver failure (a sudden worsening of liver function in someone with chronic liver disease)
- You have a hospital-acquired infection (developing 48 hours or more after being admitted) that is caused by carbapenem-resistant bacteria (bacteria that do not respond to common strong antibiotics)
- You are not in severe septic shock with failure of multiple organs
- You do not have an allergy to meropenem or ceftazidime-avibactam
- You are not already taking one of these study drugs for more than 48 hours
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving antibiotics chosen specifically for your resistant bacteria before a liver transplant can prevent infections better than the usual standard antibiotics. It aims to improve recovery and lower the risk of serious infection after surgery.
This study tests two ways of giving the antibiotic ceftazidime/avibactam (as a continuous drip or as intermittent shots) to patients in the intensive care unit with severe infections. The goal is to see which method works better or is safer for critically ill patients.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This trial compares two common antibiotic combinations to see which one is less likely to cause kidney injury in hospitalized patients. You may be eligible if you need treatment with vancomycin plus either piperacillin-tazobactam or cefepime.
This trial tests two different antibiotic combinations (ampicillin/sulbactam and cefoperazone/sulbactam) to see which works better against a type of bacteria (Acinetobacter baumannii) that is resistant to many other drugs. It is for critically ill patients with signs of sepsis.
Hear when a new Acute-On-Chronic Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.